Dr. Richard Peck
Global Head of Clinical Pharmacology for Roche
Dr Richard Peck trained in pharmacology and medicine at Cambridge University and has over thirty years’ experience of pharmaceutical industry clinical pharmacology in GlaxoWellcome and Eli Lilly before he joined Roche. His research interests include understanding and utilising variability in drug response to improve drug dosing and clinical benefit in different patient groups; applying clinical pharmacology to enable the development of personalised/stratified medicines and the use of model-based drug development strategies.
Sunday 19th September
16.45 – 17.30
Plenary Lecture | Precision Dosing: A view from industry
Dr. Carlo Locatelli
Head of Pavia Poison Control Centre – National Toxicology Information Centre ad Laboratories of Clinical and Experimental Toxicology, Istituti Clinici Scientifici Maugeri IRCCS, Pavia. Italy
Medical doctor, Intensivist and clinical toxicologist, PhD in Occupational Medicine and Industrial Hygiene. Professor of Toxicology in the Golgi Course, Medicine and Surgery, and Contract Professor at the University of Pavia (School of Specialization in Pharmacology and Clinical Toxicology) and in some masters. Former president of the Italian Society of Toxicology (SITOX) and founder of the Italian Society of Emergency Medicine (SIMEU) and the Academy of Emergency Medicine and Care (ACEMC). Member of the National Food Safety Committee and clinical coordinator of the National Antidotes Stockpile (Italian Ministry of Health). Coordinator for clinical-toxicological aspects of the National Early Warning System for drugs of abuse (Department of Drug Control Policy-Presidency of the Council of Ministers), specifically dedicated to the evaluation of poisonings and adverse effects due to the novel psychoactive substances. His research interest includes antidotes and acute poisonings, substances of abuse, food poisoning, drug safety, hospital and pre-hospital organization and management of major toxicological emergencies (accidents and chemical terrorism).
Monday 20th September
09.00 – 09.45
Plenary Lecture | The New Psychoactive Substances: availability, effects and new diagnostic needs
Dr. Stefano Finazzi
Head of the Laboratory of Clinical Data Science, Mario Negri Institute for Pharmacological Research – IRCCS, Ranica (BG), Italy.
Dr. Stefano Finazzi graduated in Physics at Scuola Normale Superiore di Pisa in 2007 and obtained a PhD in Astrophysics in 2011 and a PhD in Life, Health and Chemical Sciences in 2019. His current research interests includes: mathematical modeling of pathophysiological mechanisms in critically ill patients, evaluation of the quality of care, and data management of large databases from electronic health records.
Tuesday 21st September
08.45 – 09.30
Plenary Lecture | Precision medicine and information technology in ICUs
Dr. Manuela Neuman
Professor of Pharmacology and Toxicology, Temerity Faculty of Medicine, University of Toronto, Canada.
Dr. Neuman contributed greatly to Clinical Toxicology research and education, her scientific work has been dedicated to toxicology, both in basic science and clinical translational research. She has a long-standing dedication to the International Association of Therapeutics, Drug Monitoring and Clinical Toxicology from its inception. In addition, Dr. Neuman is an active member of a multitude of international scientific associations focusing on toxicology and a member of several committees of the IATDMCT. She held leadership roles on Clinical Toxicology and Drug of Misuse Committee (8 years a Vice Chair and 8 years as Chair of the Committee) and she promoted the IATDMCT at other international professional societies. Her contributions to the field of toxicology, as well as teaching and mentoring at all levels of education, have been recognized internationally. Her achievements reflect an outstanding output and commitment to clinical toxicology. Furthermore Dr. Neuman was recently awarded with the 2021 CSCC Award for Research Excellence.
Wednesday 22nd September
14.45 – 15.30
Plenary Lecture | Clinical importance and pharmacological utility of using biomarkers in diagnosis of dementia